Marrero, LA – April 10, 2025 | Prolerity Clinical Research, a leading clinical research site network, that owns and operates research sites across Louisiana, Florida, New Jersey, and New York, is pleased to announce the appointment of Stacey Johnson as its new Chief Operating Officer (COO). In this role, Stacey will oversee network-wide operations, support strategic initiatives, and drive growth through network expansion.

Stacey is a seasoned clinical research executive who brings more than 20 years of experience in the clinical research ecosystem, having most recently served as VP of Clinical Operations at WCG, COO at Meridien Clinical Research, and in prior executive roles in the research site industry. With a strong background in all aspects of site operations and quality, she is well-positioned to enhance operational efficiency and expand Prolerity’s market presence.

“We could not be more fortunate to have Stacey join the Prolerity team,” said Jeff Williams, CEO of Prolerity, “Stacey’s leadership, vision, and commitment to the highest standards of quality align perfectly with our mission, and we are confident that she will be instrumental in shaping our future.”

Stacey expressed enthusiasm about joining Prolerity Clinical Research, stating, “I am excited to join a team committed to being a high-value site network partner for biopharmaceutical companies and CROs who need sites capable of delivering access to diverse patients to advance their most promising treatments.”

Prolerity is a research site network with therapeutic coverage across complex and challenging Phase I–III trials, including gastroenterology, cardiology, CNS, and metabolic diseases. Prolerity owns and operates New Orleans–based Tandem Clinical Research and Florida-based ClinCloud, both known for operating best-in-class research sites for NASH/NAFLD and CNS/neurodegenerative studies by demonstrating excellence in study feasibility, contracting, patient recruitment, patient retention, and quality. 

Prolerity also operates all of the clinical research within Allied Digestive Health, the largest gastroenterology and hepatology practice in the Northeastern US (third largest in the country) with 80+ locations and 350+ providers in NJ and NY, specializing in liver disorders, cardiometabolic, IBD, GERD, Celiac Disease, and GI diagnostic/screening trials.

About Prolerity Clinical Research
Prolerity Clinical Research strives to advance medicine while improving patients’ quality of life through clinical research. Prolerity’s team is committed to serving diverse populations while ensuring our drug development customers can achieve their study objectives across our growing network of sites in Louisiana, Florida, New York, and New Jersey.

For more information, please contact us.

December 04, 2024 – Marrero, LA — Prolerity Clinical Research (“Prolerity”), a leading clinical research site network and an AHP portfolio company, announced today the appointments of Erica Prowisor as Executive Vice President of Transformation and Patient Engagement, and Michael Smith as Chief Commercial Officer. Prolerity currently owns and operates 11 research sites across Louisiana, Florida, New Jersey, and New York.

“I could not be more fortunate to have Erica and Michael join the Prolerity management team as we continue to invest in our site management network,” said Jeff Williams, CEO of Prolerity. “We are privileged to benefit from Erica’s expertise, innovative thinking in recruitment and patient engagement, and Michael’s leadership and deep knowledge in CRO and site management. Both executives will be key contributors to fueling our growth and extending our reach to patients who can benefit from the important research we conduct on behalf of our pharma and biotech sponsors.”

Prolerity is a research site network with therapeutic coverage across complex and challenging Phase I–III trials, including gastroenterology, cardiometabolic, CNS, and liver diseases.

“I am excited about the opportunity to join Prolerity to ensure that we excel at meeting the needs of patients and drug developers,” said Erica Prowisor. “We will work to innovate our recruitment function to provide even more value for our customers who rely on our sites, talented investigators, and staff.” Previously, Erica was Senior Vice President of Patients and Provider Networks at Science 37. Prior to that, she worked at IQVIA and Accurian, a recruitment company within PPD.

“Like Erica, I too am thrilled to be working on this mission with Prolerity,” said Michael Smith. “Prolerity’s group of sites has built a strong reputation in key challenging areas of research that require focus, experience, and efficient patient access to advance promising treatments into the hands of doctors and patients.” Most recently, Michael was Chief Commercial Officer at Javara. Prior to that, he worked for Syneos Health.

Prolerity owns New Orleans–based Tandem Clinical Research (“Tandem”), known for operating best-in-class research sites for NASH/NAFLD and neurodegenerative studies by demonstrating excellence in study feasibility, contracting, patient recruitment, patient retention, and quality. Tandem recently expanded into its newly developed, purpose-built 12,000 sq ft headquarters in Marrero, LA, and a new 13,000 sq ft space in Maitland, FL, through its ClinCloud division.

About Prolerity Clinical Research

Prolerity Clinical Research strives to advance medicine while improving patients’ quality of life through clinical research. Prolerity’s team is committed to serving diverse populations while ensuring our drug development customers can achieve their study objectives across our growing network of sites in Louisiana, Florida, New York, and New Jersey. Contact: media [at] prolerity [dot] com.